Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 6, 2010, Pages 383-399

  Jones, M P ^a   Nicholl, D ^b   Trakas, K ^c  

^a MACQUARIE UNIVERSITY   (Australia)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Janssen Ortho Inc   (Canada)

Author keywords

Antipsychotics; Efficacy; Meta analysis; Paliperidone ER; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE;

AGITATION; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; PATIENT SELECTION; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN;

EID: 77952764436     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48383     Document Type: Article

References (68)

1. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004; 161: 414-425.
2. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs. 2002; 16: 473-484.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003; 60: 553-564.
4. Pani L, Pira L, Marchese G. Antipsychotic efficacy: relationship to optimal D(2)-receptor occupancy. Eur Psychiatry. 2007; 22: 267-278.
5. Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology. 2007; 32: 1715-1726.
6. DeVane CL. Brief comparison of the pharmacokinetics and pharmacodynamics of the traditional and newer antipsychotic drugs. Am J Health Syst Pharm. 1995; 52: S15-S18.
7. Vermir M, Boom S, Naessens I, Talluri K, Eerdekens M. Absorption, metabolism and excretion of a single oral dose of 1mg paliperidone in a population of five healthy male subjects. Eur Neuropsychopharmacol. 2005; 15 (Suppl 3): S648.
8. Kane J, Canas F, Kramer M et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007; 90: 147-161.
9. Marder SR, Kramer M, Ford L et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007; 62: 1363-1370.
10. Davidson M, Emsley R, Kramer M et al. Efficacy, safety and early response of paliperidone extended- release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007; 93: 117-130.
11. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1-12.
12. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996; 124: 159-167. (Pubitemid 126424654)
13. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996; 14: 111-123. (Pubitemid 26050500)
14. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997; 42: 233-246.
15. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151: 825-835.
16. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209-1223. (Pubitemid 41345943)
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188.
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634. (Pubitemid 27387172)
19. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992; 28: 213-218.
20. Fabre LF Jr, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther. 1995; 17: 366-378.
21. Yeung P, McQuade RD, Carson WH, Saha A, Ali MW, Ingenito G. Aripiprazole and risperidone versus placebo in schizophrenia. Eur Psychiatry. 2002; 16: S102.
22. Daniel DG, Saha AR, Ingenito G, Carson G, Dunbar G. Aripiprazole, a novel antipsychotic: overview of a Phase II study result. Neuropsychopharmacology. 2000; Suppl 1: S157.
23. Beasley CM, Walker DJ, Sutton VK, Alaka K, Naber D, Namjoshi M. The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. Eur Neuropsychopharmacol. 2003; 13: S342.
24. Tollefson GD, Dellva MA, Mattler CA, Kane JM, Wirshing DA, Kinon BJ. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. JClin Psychopharmacol. 1999; 19: 435-443.
25. Lecrubier Y, Bouhassira M, Olivier V, Lancrenon S, Crawford AM. Olanzapine versus amisulpride and placebo in the treatment of negative symptoms and deficit states of chronic schizophrenia. Eur Neuropsychopharmacol. 1999; 9: S288.
26. Csernansky J, Garbott J, Goff DC, Green AI, Jeste DV, Karson C. Abilify (aripiprazole) tablets: Study 93202. Medical review, parts 1-4; 2002. www.fda.gov/cder/foi/nda/2002/21-436-Abilify.htm. Accessed July 5, 2007.
27. Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability - are patients better off? Can J Psychiatry. 2004; 49: 297-302.
28. Srisurapanont M, Maneeton N. Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials. J Med Assoc Thai. 1999; 82: 341-346. (Pubitemid 29367341)
29. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999; 35: 51-68.
30. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54: 549-557
31. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. JClin Psychopharmacol. 1996; 16: 158-169.
32. Potkin SG, Gharabawi GM, Greenspan AJ et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006; 85: 254-265.
33. Canuso C, Carothers J, Dirks B et al. A double-blind, placebo-controlled trial comparing paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Poster presented at: the Collegium Internationale Neuro- Psychopharmacologicum 2008 Annual Meeting; July 13-17, 2008; Munich, Germany.
34. Dirks B, Eerdekens M, Turkoz I, Alberio R, Gharabawi G. Efficacy of paliperidone extended-release tablets in patients with schizophrenia and predominant negative symptoms. Int J Neuropsychopharmacol. 2006; 9: S1, doi, 225.
35. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow- up. Am J Psychiatry. 2005; 162: 495-506. (Pubitemid 40343916)
36. Diels J, Trakas K, Nichol D, Nuyts G. Direct healthcare costs after initiation of oral antipsychotic treatment for schizophrenia: efficacy versus tolerability. Poster presented at: the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders; February 3-7, 2008; Montreux, Switzerland.
37. Diels J, Trakas K, Nichol D, Nuyts G. Analysis of psychiatric hospitalization after initiation of oral antipsychotic treatment for schizophrenia. Poster presented at: the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders; February 3-7, 2008; Montreux, Switzerland.
38. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003; 64: 1048-1056.
39. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004; 24: S7-S14.
40. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001; 62 (Suppl 7): 22-31.
41. Allison DB, Mentore JL, Heo M et al. Antipsychotic- induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156: 1686-1696. (Pubitemid 29517559)
42. Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry. 2008; 69 (Suppl 1): 18-31.
43. Jayaram MB, Hosalli PM, Stroup TS. Risperidone versus olanzapine for treatment of schizophrenia. Schizophr Bull. 2007; 33: 1274-1276. (Pubitemid 350022780)
44. Luthringer R, Staner L, Noel N et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol. 2007; 22: 299-308.
45. Rossenu S, Cleton A, Talluri K et al. Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone and an immediate-release Poster presented at: the American Society for Clinical Pharmacology and Therapeutics Annual Meeting; Anaheim, CA.
46. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005; 66: 15-27.
47. Invega [package insert]. Titusville, NJ: Janssen, L.P.; 2007.
48. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007; 100: 4-22.
49. Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161: 1-56.
50. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs. 2006; 20: 293-301.
51. Blanchard JJ, Brown SA, Horan WP, Sherwood AR. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin Psychol Rev. 2000; 20: 207-234. (Pubitemid 30100433)
52. de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res. 2002; 56: 47-54. (Pubitemid 34655467)
53. Mann A, Miksys S, Lee A, Mash DC, Tyndale RF. Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology. 2008; 55: 1145-1155 [Epub 2008 Jul 19].
54. Pasanen M, Pellinen P, Stenback F, Juvonen RO, Raunio H, Pelkonen O. The role of CYP enzymes in cocaine-induced liver damage. Arch Toxicol. 1995; 69: 287-290.
55. Sheweita SA. Narcotic drugs change the expression of cytochrome P450 2E1 and 2C6 and other activities of carcinogen-metabolizing enzymes in the liver of male mice. Toxicology. 2003; 191: 133-142.
56. Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull. 2007; 40: 77-97.
57. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother. 2006; 6: 1249-1265.
58. Alphs L, Turkoz I, Bossie CA, Canuso CM, Kujawa M. Placebo responses in controlled clinical trials of patients with schizophrenia: a decade of differences. Poster presented at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders; February 3-7, 2008; Montreux, Switzerland.
59. Chouinard G, Jones B, Remington G et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993; 13: 25-40.
60. Adson D, Bari M, Bona J, Garner DL, Hafez H, Janiceck PG. Abilify (aripiprazole) tablets: Study 138001. Medical review, parts 1-4; 2002. www.fda.gov/cder/foi/nda/2002/21-436-Abilify.htm. Accessed July 5, 2007.
61. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002; 63: 763-771.
62. McEvoy JP, Beitman R, Borison RL, Brown D, Canive JM, Lauriello J. Abilify (aripiprazole) tablets: Study 94202. Medical review, parts 1-4; 2002. www.fda.gov/cder/foi/nda/2002/21-436-Abilify.htm. Accessed July 5, 2007.
63. Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003; 60: 681-690.
64. Corrigan MH, Gallen CC, Bonura ML, Merchant KM. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Biol Psychiatry. 2004; 55: 445-451.
65. Borison RL. Risperidone versus haloperidol vs placebo in the treatment of schizophrenia. Clinical Research Report No: RIS-USA-9001; 1991.
66. Eerdekens M, Kramer M, Rossenu S et al. Effect of paliperidone extend-release tablets on prolactin exposure in patients with stable schizophrenia. Poster presented at: US Psychiatric & Mental Health Congress; 2006.
67. Morton SC, Adams JL, Suttorp MJ, Shekelle PG. Meta-regression Approaches: What, Why, When, and How? Technical Review 8 (Prepared by Southern California- RAND Evidence-based Practice Center, under Contract No 290-97-0001). Rockville, MD: Agency for Healthcare Research and Quality; 2004. AHRQ Publication No. 04-0033.
68. Risperidal [package insert]. Titusville, NJ: Janssen, L.P.; 2008.